Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.